S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
All the trading advice you’ve ever received boils down to this (Ad)
Freshworks gets juiced on its AI customer engagement platform
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
Much of Kenya falls into darkness in the third nationwide power blackout in 3 months
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Biden goes into 2024 with the economy getting stronger, but voters feel horrible about it
3 tech outperformers adored by analysts
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
All the trading advice you’ve ever received boils down to this (Ad)
Freshworks gets juiced on its AI customer engagement platform
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
Much of Kenya falls into darkness in the third nationwide power blackout in 3 months
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Biden goes into 2024 with the economy getting stronger, but voters feel horrible about it
3 tech outperformers adored by analysts
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
All the trading advice you’ve ever received boils down to this (Ad)
Freshworks gets juiced on its AI customer engagement platform
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
Much of Kenya falls into darkness in the third nationwide power blackout in 3 months
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Biden goes into 2024 with the economy getting stronger, but voters feel horrible about it
3 tech outperformers adored by analysts
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
All the trading advice you’ve ever received boils down to this (Ad)
Freshworks gets juiced on its AI customer engagement platform
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
Much of Kenya falls into darkness in the third nationwide power blackout in 3 months
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Biden goes into 2024 with the economy getting stronger, but voters feel horrible about it
3 tech outperformers adored by analysts

Generation Bio (GBIO) Stock Price, News & Analysis

$1.71
-0.06 (-3.39%)
(As of 12/8/2023 08:57 PM ET)
Compare
Today's Range
$1.60
$1.93
50-Day Range
$0.91
$3.35
52-Week Range
$0.86
$7.35
Volume
688,900 shs
Average Volume
392,424 shs
Market Capitalization
$112.99 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.56

Generation Bio MarketRank™ Stock Analysis

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
400.4% Upside
$8.56 Price Target
Short Interest
Bearish
6.34% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.33mentions of Generation Bio in the last 14 days
Based on 8 Articles This Week
Insider Trading
Acquiring Shares
$18,000 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($1.88) to ($1.66) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.21 out of 5 stars

Medical Sector

335th out of 942 stocks

Biotechnology Industry

9th out of 41 stocks


GBIO stock logo

About Generation Bio Stock (NASDAQ:GBIO)

Generation Bio Co., a genetic medicines company, develops therapies for the treatment of rare and prevalent diseases. The company provides a portfolio of programs, including programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

GBIO Stock Price History

GBIO Stock News Headlines

Charles Rowland Bought 179% More Shares In Generation Bio
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology
Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
JMP Securities Keeps Their Hold Rating on Generation Bio (GBIO)
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology
Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Generation Bio GAAP EPS of -$0.43
JMP Securities downgrades Generation Bio (GBIO) to a Hold
TD Cowen Downgrades Generation Bio (GBIO)
See More Headlines
Receive GBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Generation Bio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2023
Today
12/10/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/22/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GBIO
Fax
N/A
Employees
150
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$8.56
High Stock Price Target
$14.00
Low Stock Price Target
$2.23
Potential Upside/Downside
+400.4%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
6 Analysts

Profitability

Net Income
$-136,640,000.00
Pretax Margin
-4,092.23%

Debt

Sales & Book Value

Annual Sales
$3.03 million
Book Value
$4.75 per share

Miscellaneous

Free Float
52,334,000
Market Cap
$112.99 million
Optionable
Not Optionable
Beta
2.49
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Dr. Cameron Geoffrey McDonough M.D. (Age 53)
    President, CEO & Director
    Comp: $939.09k
  • Dr. Matthew Norkunas M.B.A. (Age 45)
    M.D., Chief Financial Officer
    Comp: $611.11k
  • Dr. Matthew Stanton Ph.D. (Age 50)
    Chief Scientific Officer
    Comp: $654.83k
  • Dr. Douglas Kerr M.B.A. (Age 56)
    M.D., Ph.D., Chief Medical Officer
    Comp: $659.1k
  • Dr. Tracy Zimmermann Ph.D. (Age 53)
    Chief Development Officer
    Comp: $622.74k
  • Dr. Mark D. Angelino Ph.D. (Age 50)
    Co-Founder
  • Dr. Robert Kotin Ph.D. (Age 67)
    Co-Founder
  • Ms. Antoinette Paone M.B.A. (Age 45)
    M.S., Chief Operating Officer
  • Ms. Yalonda Howze J.D. (Age 51)
    Chief Legal Officer & Secretary
  • Ms. Jasmin Tower
    Senior Vice President of People & Operations














GBIO Stock Analysis - Frequently Asked Questions

Should I buy or sell Generation Bio stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Generation Bio in the last year. There are currently 4 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" GBIO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GBIO, but not buy additional shares or sell existing shares.
View GBIO analyst ratings
or view top-rated stocks.

What is Generation Bio's stock price target for 2024?

6 brokerages have issued 1-year price objectives for Generation Bio's shares. Their GBIO share price targets range from $2.23 to $14.00. On average, they predict the company's share price to reach $8.56 in the next twelve months. This suggests a possible upside of 400.4% from the stock's current price.
View analysts price targets for GBIO
or view top-rated stocks among Wall Street analysts.

How have GBIO shares performed in 2023?

Generation Bio's stock was trading at $3.93 at the beginning of the year. Since then, GBIO shares have decreased by 56.5% and is now trading at $1.71.
View the best growth stocks for 2023 here
.

Are investors shorting Generation Bio?

Generation Bio saw a increase in short interest in November. As of November 15th, there was short interest totaling 3,090,000 shares, an increase of 76.6% from the October 31st total of 1,750,000 shares. Based on an average daily trading volume, of 569,000 shares, the days-to-cover ratio is currently 5.4 days. Currently, 6.3% of the company's shares are sold short.
View Generation Bio's Short Interest
.

When is Generation Bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 22nd 2024.
View our GBIO earnings forecast
.

How were Generation Bio's earnings last quarter?

Generation Bio Co. (NASDAQ:GBIO) posted its quarterly earnings results on Thursday, November, 9th. The company reported ($0.43) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.51) by $0.08. The company earned $2.15 million during the quarter, compared to analysts' expectations of $2.26 million.

What other stocks do shareholders of Generation Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Generation Bio investors own include DocuSign (DOCU), NVIDIA (NVDA), Overstock.com (OSTK), Boeing (BA), Pure Storage (PSTG), Mastercard (MA), QUALCOMM (QCOM), Riot Platforms (RIOT), Twilio (TWLO) and Enphase Energy (ENPH).

When did Generation Bio IPO?

(GBIO) raised $126 million in an initial public offering (IPO) on Friday, June 12th 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Jefferies and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Who are Generation Bio's major shareholders?

Generation Bio's stock is owned by a variety of institutional and retail investors. Top institutional investors include FMR LLC (12.79%), TD Asset Management Inc (0.62%), Wellington Management Group LLP (0.27%), GSA Capital Partners LLP (0.06%), American Century Companies Inc. (0.05%) and SG Americas Securities LLC (0.02%). Insiders that own company stock include Antoinette Paone, Charles A Rowland Jr, Dannielle Appelhans, Donald William Nicholson, Douglas Kerr, Evan Spiegel, Geoff Mcdonough, Jason P Rhodes, Matthew Stanton, Phillip Samayoa and Venture Associates X L Atlas.
View institutional ownership trends
.

How do I buy shares of Generation Bio?

Shares of GBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:GBIO) was last updated on 12/11/2023 by MarketBeat.com Staff

My Account -